目的 探讨同步放化疗与序贯放化疗对局部晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者近远期生 存率的影响。方法 选取62例局部晚期NSCLC患者随机分为两组，其中31例患者给予同步放化疗治疗为观察组，另31 例患者给予序贯放化疗治疗为对照组，观察两组近期疗效、不良反应、近远期生存率及生活质量。结果 观察组和 对照组缓解率(remission rate, RR)分别为(74.17%和45.16%，P<0.05)；两组患者Ⅲ-Ⅳ期不良反应发生差异不显 著(P>0.05)；观察组1年、2年及3年的生存率分别为87.10%、70.97%及48.39%，均高于对照组的64.52%、45.16%及 22.58%(P<0.05)；观察组和对照组的生活质量提高率分别为(29.03%和6.45%，P<0.05)。结论 同步放化疗治疗局部 晚期NSCLC患者疗效较序贯放化疗更显著，可有效延长患者生存期，改善其生活质量，安全性高。

Objective To investigate the effects of concurrent and sequential chemoradiotherapy on the short and long term survival rates in patients with locally advanced non-small cell lung cancer (NSCLC). Methods 62 patients with locally advanced NSCLC were randomly divided into observation group (31 cases) and control group (31 cases). The observation group was given concurrent chemoradiotherapy, while the control group was given sequential chemoradiotherapy. The short term effects, adverse reactions, short and long term survival rates and quality of life in the two groups were observed and compared. Results The remission rate (RR) in the observation group was 74.17% which was significantly higher than that in the control group 45.16% (P<0.05), there were no significant differences in the incidence of adverse reactions at stage Ⅲ～Ⅳ (P>0.05), the survival rates of 1, 2 and 3 years in the observation group were 87.10%, 70.97% and 48.39%which were all significantly higher than those in the control group 64.52%, 45.16% and 22.58% (P<0.05), the increase ratio of life quality in the observation group was 29.03% which was significantly higher than that in the control group 6.45% (P<0.05). Conclusion Concurrent chemoradiotherapy which has better effect and higher safety for patients with locally advanced NSCLC, can not only prolong the survival time, but also improve the life quality of patients.